Principle Investigator: Sharad Ghamande, MD “GOG-0229O; A Randomized Phase II Study with a Safety Lead-in to Assess the Antitumor Efficacy of the MEK Inhibitor Trametinib Alone or in Combination with GSK2141795, an AKT Inhibitor, in Patients with...
Principle Investigator: Sharad Ghamande, MD “GOG-0229O; A Randomized Phase II Study with a Safety Lead-in to Assess the Antitumor Efficacy of the MEK Inhibitor Trametinib Alone or in Combination with GSK2141795, an AKT Inhibitor, in Patients with...